LON:OBD Oxford BioDynamics Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oxford BioDynamics Plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 13.85 +0.35 (+2.59%) (As of 07/1/2022 04:35 PM ET) Add Compare Share Today's Range 13.50▼ 14.4550-Day Range 12.32▼ 21.8852-Week Range 11.25▼ 62.80Volume97,137 shsAverage Volume317,417 shsMarket Capitalization£13.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlines Oxford BioDynamics Stock Forecast (MarketRank)Analyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 4 Articles This WeekInsider TradingAcquiring Shares£965 K Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.51 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Oxford BioDynamics. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for OBD. Previous Next 0.0 Dividend Strength Dividend YieldOxford BioDynamics does not currently pay a dividend.Dividend GrowthOxford BioDynamics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OBD. Previous Next 1.7 News and Social Media Coverage News SentimentOxford BioDynamics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Oxford BioDynamics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford BioDynamics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £9,650 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford BioDynamics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford BioDynamics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford BioDynamics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford BioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Oxford BioDynamics (LON:OBD)Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.Read More OBD Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comOxford BioDynamics (LON:OBD) Rating Reiterated by Shore CapitalJune 28, 2022 | lse.co.ukOxford BioDynamics shares drop as it might need funding by early 2023June 21, 2022 | barrons.comOxford BioDynamics's Checkpoint Inhibitor Response Test (EpiSwitch(R) CiRT) Now Available in the UKJune 19, 2022 | americanbankingnews.comOxford BioDynamics (LON:OBD) Hits New 52-Week Low at $16.00March 11, 2022 | finance.yahoo.comOxford BioDynamics Plc (OBD.L)November 22, 2021 | finance.yahoo.comIs Oxford BioDynamics (LON:OBD) In A Good Position To Deliver On Growth Plans?October 25, 2021 | marketwatch.comArmistice Capital Invests GBP3.6 Mln in Oxford BioDynamicsAugust 31, 2021 | lse.co.ukGeronimo the alpaca euthanised in Britain despite public outcryAugust 31, 2021 | lse.co.ukTRADING UPDATES: Jet2 in bumper Airbus order; Strix China factory liveAugust 31, 2021 | lse.co.ukRyanair predicts strong recovery, ups passenger targetAugust 31, 2021 | lse.co.ukOxford BioDynamics awarded $0.91m US PACT grantAugust 31, 2021 | finance.yahoo.comOxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer TherapiesJuly 29, 2021 | marketwatch.comGenetic Testing Market is projected to manifest the fastest CAGR of 11.53% through 2027See More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:OBD CUSIPN/A CIKN/A Webwww.oxfordbiodynamics.com Phone+44-1865-518910FaxN/AEmployees39Year FoundedN/ACompany Calendar Last Earnings6/16/2020Today7/01/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio99.34 Current Ratio2.98 Quick Ratio2.80 Sales & Book Value Annual Sales£176 thousand Price / Sales78.97 Cash FlowGBX 5.28 per share Price / Cash Flow2.62 Book ValueGBX 6.60 per share Price / Book2.10Miscellaneous Outstanding Shares100,352,000Free FloatN/AMarket Cap£13.90 million OptionableNot Optionable BetaN/A Oxford BioDynamics Frequently Asked Questions How has Oxford BioDynamics' stock performed in 2022? Oxford BioDynamics' stock was trading at GBX 38.25 at the beginning of 2022. Since then, OBD shares have decreased by 63.8% and is now trading at GBX 13.85. View the best growth stocks for 2022 here. How were Oxford BioDynamics' earnings last quarter? Oxford BioDynamics Plc (LON:OBD) announced its earnings results on Tuesday, June, 16th. The biotechnology company reported ($2.20) earnings per share (EPS) for the quarter. View Oxford BioDynamics' earnings history. Who are Oxford BioDynamics' key executives? Oxford BioDynamics' management team includes the following people: Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D., CEO & Director (Age 59, Pay $463k)Mr. Paul Leslie Stockdale F.C.A., M.A., CFO & Director (Age 47, Pay $202k)Dr. Alexandre Akoulitchev Ma (Oxon), Ph.D., Chief Scientific Officer & Director (Age 60, Pay $236k)Mr. Thomas G. Guiel B.A., Chief Operating OfficerDr. Jayne Green B.Sc., Ph.D., Director of OperationsDr. Aroul Ramadass M.Sc., Ph.D., Ph.D.(CANTAB), PDF (OXON), FCPS, FRA, Chief Technology OfficerDr. Ewan Hunter B.Sc., Ph.D., BSC, Ph.D., (KCL), Group CDOMr. Bipin Patel, Head of RA/QAT. Demain, Company Sec.Dr. Steven Tucker M.D., FACP, Group Clinical Director Who are some of Oxford BioDynamics' key competitors? Some companies that are related to Oxford BioDynamics include Burcon NutraScience (BU), Devonian Health Group (GSD), Asterias Biotherapeutics (AST), Emerald Health Therapeutics (EMH), C4X Discovery (C4XD), 4basebio (4BB), Acasti Pharma (ACST), Ceapro (CZO), Helix BioPharma (HBP), OKYO Pharma (OKYO), SkinBioTherapeutics (SBTX), Small Pharma (DMT), Virios Therapeutics (VIRI), Tissue Regenix Group (TRX) and Antibe Therapeutics (ATE). View all of OBD's competitors. What other stocks do shareholders of Oxford BioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioDynamics investors own include Oxford Biomedica (OXB), Frontline (FRO), Fate Therapeutics (FATE), Cargojet (CJT), China Unicom (Hong Kong) (CHU), Casey's General Stores (CASY), Buckle (BKE), Biffa (BIFF), AXT (AXTI) and Grupo Aval Acciones y Valores (AVAL). What is Oxford BioDynamics' stock symbol? Oxford BioDynamics trades on the London Stock Exchange (LON) under the ticker symbol "OBD." How do I buy shares of Oxford BioDynamics? Shares of OBD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Oxford BioDynamics' stock price today? One share of OBD stock can currently be purchased for approximately GBX 13.85. How much money does Oxford BioDynamics make? Oxford BioDynamics (LON:OBD) has a market capitalization of £13.90 million and generates £176 thousand in revenue each year. How many employees does Oxford BioDynamics have? Oxford BioDynamics employs 39 workers across the globe. How can I contact Oxford BioDynamics? Oxford BioDynamics' mailing address is 26 Beaumont Street, OXFORD, OX1 2NP, United Kingdom. The official website for Oxford BioDynamics is www.oxfordbiodynamics.com. The biotechnology company can be reached via phone at +44-1865-518910. This page (LON:OBD) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
